NNMX Stock Overview
Nanomix Corporation develops and commercializes mobile point-of-care diagnostic system that is used in performing a range of in vitro diagnostic tests in various environments.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nanomix Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.15 |
| 52 Week Low | US$0.0001 |
| Beta | 1.16 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NNMX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 0.007% | 0.7% |
| 1Y | -99.9% | -1.0% | 23.9% |
Return vs Industry: NNMX underperformed the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: NNMX underperformed the US Market which returned 29.5% over the past year.
Price Volatility
| NNMX volatility | |
|---|---|
| NNMX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NNMX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NNMX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 30 | David Ludvigson | nanomixdx.com |
Nanomix Corporation develops and commercializes mobile point-of-care diagnostic system that is used in performing a range of in vitro diagnostic tests in various environments. Its products are designed to enhance healthcare delivery by bringing diagnostic information to the point of initial patient interaction, whether in the hospital or in settings, such as nursing facilities, elderly homes, urgent care centers, airports, schools, and others. The company is also developing a pipeline of other tests designed to enhance patient outcomes by making diagnostic information available.
Nanomix Corporation Fundamentals Summary
| NNMX fundamental statistics | |
|---|---|
| Market cap | US$4.90k |
| Earnings (TTM) | -US$12.53m |
| Revenue (TTM) | US$15.45k |
0.3x
P/S Ratio0.0x
P/E RatioIs NNMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNMX income statement (TTM) | |
|---|---|
| Revenue | US$15.45k |
| Cost of Revenue | US$0 |
| Gross Profit | US$15.45k |
| Other Expenses | US$12.55m |
| Earnings | -US$12.53m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 100.00% |
| Net Profit Margin | -81,114.23% |
| Debt/Equity Ratio | -82.2% |
How did NNMX perform over the long term?
See historical performance and comparison